Doximity (NYSE:DOCS) Director Sells $57,820.00 in Stock

Doximity, Inc. (NYSE:DOCS) Director Kira Wampler sold 2,000 shares of the business’s stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $28.91, for a total transaction of $57,820.00. Following the completion of the sale, the director directly owned 27,923 shares of the company’s stock, valued at $807,253.93. This represents a 6.68% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kira Scherer Wampler also recently made the following trade(s):

• On Tuesday, August 25th, Kira Wampler sold 2,000 shares of Doximity stock. The shares were sold at an average price of $24.95, for a total transaction of $49,900.00.

Doximity Trading Down 0.3%

Shares of NYSE:DOCS opened at $27.70 on Thursday. The stock’s 50-day moving average price is $25.60 and its 200-day moving average price is $23.32. Doximity, Inc. has a 12-month low of $17.15 and a 12-month high of $73.92. The stock has a market capitalization of $4.94 billion, a P/E ratio of 32.59, a price-to-earnings-growth ratio of 21.74 and a beta of 1.22.

Doximity (NYSE:DOCS) last released its earnings results on Thursday, August 6th. The company reported $0.29 earnings per share for the quarter, beating analysts’ consensus estimates of $0.16 by $0.13. The company had revenue of $156.62 million during the quarter. Doximity had a return on equity of 18.06% and a net margin of 25.48%.The company’s revenue was up 7.3% on a year-over-year basis. During the same period last year, the firm posted $0.36 EPS. As a group, research analysts predict that Doximity, Inc. will post 0.74 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the company. JPMorgan Chase & Co. increased their price objective on Doximity from $26.00 to $31.00 and gave the company a “neutral” rating in a research note on Friday, August 7th. Bank of America reaffirmed an “underperform” rating and issued a $20.00 target price (down from $38.00) on shares of Doximity in a research note on Monday, June 29th. Weiss Ratings upgraded shares of Doximity from a “hold (c-)” rating to a “hold (c)” rating in a report on Tuesday. Zacks Research raised shares of Doximity from a “strong sell” rating to a “hold” rating in a research report on Monday, July 13th. Finally, Freedom Capital lowered shares of Doximity from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 8th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, fourteen have given a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $31.95.

Doximity News Roundup

Here are the key news stories impacting Doximity this week:

• Positive Sentiment: Doximity continues to attract investor attention because of its digital healthcare platform, clinical artificial-intelligence adoption and cash-generation potential. These longer-term growth themes may help support the shares despite near-term legal concerns. Reasons to Retain Doximity Stock in Your Portfolio for Now
• Neutral Sentiment: Director Kira Scherer Wampler sold 2,000 Doximity shares for approximately $57,820 under a pre-arranged Rule 10b5-1 trading plan. Although the transaction reduced her holdings by 6.68%, its planned nature makes it a limited signal of management’s current outlook. SEC Insider Transaction Filing
• Negative Sentiment: Several law firms, including Glancy Prongay Wolke & Rotter, Howard G. Smith, Rosen, Kaplan Fox and Levi & Korsinsky, are promoting the same securities-fraud class action concerning investors who purchased DOCS shares between August 8, 2024, and May 13, 2026. The allegations include potentially misleading statements about revenue growth, market share, Newsfeed performance and Doximity’s use of banner-advertising and e-newsletter formats. The claims have not been proven, but the growing publicity raises litigation, reputational and potential financial risks for the company. Doximity Securities Fraud Lawsuit Deadline Alert

Hedge Funds Weigh In On Doximity

Hedge funds have recently made changes to their positions in the business. Capital World Investors lifted its stake in Doximity by 5.1% in the fourth quarter. Capital World Investors now owns 5,654,875 shares of the company’s stock worth $250,398,000 after acquiring an additional 273,444 shares during the period. Carmignac Gestion raised its holdings in Doximity by 127.8% in the 1st quarter. Carmignac Gestion now owns 4,311,997 shares of the company’s stock worth $100,480,000 after purchasing an additional 2,418,971 shares in the last quarter. Wellington Management Group LLP lifted its position in shares of Doximity by 24.7% in the 2nd quarter. Wellington Management Group LLP now owns 3,135,113 shares of the company’s stock worth $65,022,000 after purchasing an additional 621,464 shares during the period. Renaissance Technologies LLC lifted its position in shares of Doximity by 29.4% in the 1st quarter. Renaissance Technologies LLC now owns 3,059,749 shares of the company’s stock worth $71,292,000 after purchasing an additional 694,300 shares during the period. Finally, SG Americas Securities LLC boosted its stake in shares of Doximity by 3,403.2% during the 1st quarter. SG Americas Securities LLC now owns 1,408,597 shares of the company’s stock valued at $32,820,000 after purchasing an additional 1,368,388 shares in the last quarter. 87.19% of the stock is owned by hedge funds and other institutional investors.

Doximity Company Profile

Doximity, Inc operates a digital platform designed for U.S. medical professionals. Its network enables physicians, nurse practitioners, physician assistants and other healthcare providers to connect with colleagues, exchange clinical information and access professional resources.

The company offers tools for telehealth and care coordination, including video and phone-based communication services, as well as digital faxing and secure messaging capabilities. Doximity also provides medical news and research content tailored to healthcare professionals.

Doximity generates additional business through recruiting and marketing solutions that help healthcare organizations reach clinicians and promote employment opportunities, services and products.